SEARCH:   Advanced

Blood, Vol. 111, Issue 5, 2843-2853, March 1, 2008 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors Blood Copland et al. 111: 2843 Supplemental materials for: Copland et al Files in this Data Supplement: Figure S1. CD34+ CML (upper panel) and normal cells (lower panel) were treated with combinations of BMS-214662 and IM or BMS-214662 and dasatinib for 72 hours at the concentrations indicated (JPG, 81.6 KB) - All results are expressed as a percentage of the no drug control. This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020